Syuan-Ting Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Syuan-Ting Chang has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Hon-Yen Wu
Division of Nephrology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan
1 shared publication - Yen-Ling Chiu
Graduate Institute of Medicine, Yuan-Ze University, Taiwan
1 shared publication - Yi-Fang Chuang
Institute of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan
1 shared publication
Latest Publications
- 30 December 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (4) , 1590-1602
Anti-herpetic treatment reduces dementia risk: A systematic review and meta-analysis
Background: Human herpesvirus (HHV) infections, particularly for herpes simplex virus (HSV) and varicella-zoster virus (VZV), may increase dementia risk, yet the protective effects of anti-herpetic medications remained unclear. Objective: This systematic review and meta-analysis of observational studies aimed to examine the association between anti-herpetic medications and dementia, focusing on HSV or VZV-related infections. Methods: This study followed PRISMA guidelines (CRD42022368318). Cohort or nested case-control studies published from databases’ inception to December 2024 were systematically searched in PubMed, MEDLINE, Embase, Cochrane Library, PsycINFO, and Web of Science. Eligible studies evaluated anti-herpetic medications (e.g., acyclovir, famciclovir, ganciclovir, valacyclovir, valganciclovir) and dementia risk in non-demented adults aged ≥50. Pooled adjusted hazard ratios (aHR) and 95% confidence intervals (CIs) were analyzed using random-effects models. Subgroup and meta-regression analyses were performed to explore potential sources of heterogeneity and effect modifiers. Results: Fourteen cohort studies involving more than 10 million older adults were included. To demonstrate the effects of anti-herpetic medications in various clinical scenarios, the meta-analysis compared: diagnosed and treated versus diagnosed but untreated (aHR=0.77, 95% CI: 0.67–0.89); treated versus untreated regardless of diagnosis (aHR=0.90, 95% CI: 0.87–0.94); and diagnosed and treated versus neither diagnosed nor treated (aHR=0.87, 95% CI: 0.78–0.97). Subgroup analysis and meta-regression identified infection severity as a significant modifier ( p < 0.0001), explaining 89.01% of heterogeneity. Conclusions: This systematic review and meta-analysis reveals notable protective effect of anti-herpetic medication usage on dementia, and the effect is especially pronounced in patients with severe alpha herpesvirus infections.
- 30 December 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (4) , 1590-1602
Anti-herpetic treatment reduces dementia risk: A systematic review and meta-analysis
Background: Human herpesvirus (HHV) infections, particularly for herpes simplex virus (HSV) and varicella-zoster virus (VZV), may increase dementia risk, yet the protective effects of anti-herpetic medications remained unclear. Objective: This systematic review and meta-analysis of observational studies aimed to examine the association between anti-herpetic medications and dementia, focusing on HSV or VZV-related infections. Methods: This study followed PRISMA guidelines (CRD42022368318). Cohort or nested case-control studies published from databases’ inception to December 2024 were systematically searched in PubMed, MEDLINE, Embase, Cochrane Library, PsycINFO, and Web of Science. Eligible studies evaluated anti-herpetic medications (e.g., acyclovir, famciclovir, ganciclovir, valacyclovir, valganciclovir) and dementia risk in non-demented adults aged ≥50. Pooled adjusted hazard ratios (aHR) and 95% confidence intervals (CIs) were analyzed using random-effects models. Subgroup and meta-regression analyses were performed to explore potential sources of heterogeneity and effect modifiers. Results: Fourteen cohort studies involving more than 10 million older adults were included. To demonstrate the effects of anti-herpetic medications in various clinical scenarios, the meta-analysis compared: diagnosed and treated versus diagnosed but untreated (aHR=0.77, 95% CI: 0.67–0.89); treated versus untreated regardless of diagnosis (aHR=0.90, 95% CI: 0.87–0.94); and diagnosed and treated versus neither diagnosed nor treated (aHR=0.87, 95% CI: 0.78–0.97). Subgroup analysis and meta-regression identified infection severity as a significant modifier ( p < 0.0001), explaining 89.01% of heterogeneity. Conclusions: This systematic review and meta-analysis reveals notable protective effect of anti-herpetic medication usage on dementia, and the effect is especially pronounced in patients with severe alpha herpesvirus infections.